Skip to main content

Table 3 Changes of plasma HbA1c, blood lipids and cardiac function between Baseline and End of Study (week 24)

From: Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Variables Liraglutide monotherapy Metformin monotherapy P Liraglutide (1.8 mg/d) monotherapy Liraglutide plus Metformin dual therapy P
BMI (kg/m2) −1.07 ± 0.23 −0.73 ± 0.14 <0.001 −1.13 ± 0.16 −1.20 ± 0.21 0.152
HbA1c (%)    0.278    0.093
 % −2.6 ± 0.3 −2.5 ± 0.4   −2.6 ± 0.4 −2.8 ± 0.5  
 mmol/mol −28 ± 3 −27 ± 4   −28 ± 0.4 −31 ± 5  
PPG (mmol/L) −5.8 ± 1.7 −5.5 ± 1.6 0.484 −5.4 ± 1.5 −5.7 ± 1.6 0.459
TC (mmol/L) −0.7 ± 0.4 −0.5 ± 0.3 0.033 −0.7 ± 0.3 −0.9 ± 0.4 0.033
LDL-C (mmol/L) −0.6 ± 0.3 −0.4 ± 0.2 0.003 −0.5 ± 0.3 −0.8 ± 0.4 0.002
CRP (mg/L) −4.3 ± 1.2 −2.4 ± 1.0 <0.001 −4.1 ± 0.8 −4.8 ± 1.0 0.004
SBP (mmHg) −11 ± 4 −4 ± 2 <0.001 −11 ± 3 −12 ± 4 0.278
DBP (mmHg) −6 ± 3 −3 ± 1 <0.001 −6 ± 3 −7 ± 4 0.278
LVEDD (mm) −9 ± 4 −5 ± 3 <0.001 −8 ± 3 −10 ± 4 0.033
EF (%) 5 ± 3 3 ± 2 0.004 5 ± 2 7 ± 3 0.004
E/A ratio 0.16 ± 0.04 0.05 ± 0.02 <0.001 0.14 ± 0.02 0.18 ± 0.04 <0.001
  1. Abbreviations: BMI body mass index, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, PPG postprandial glucose, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein, LVEDD left ventricular end-diastolic diameter, EF ejection fraction